((自动化翻译由路透提供,请见免责声明 ))
10月30日 - ** 生物技术公司 AnaptysBio 股价盘前下跌约 29% 至 21.99 美元
** 制药巨头礼来 在一份投资者简报中披露,该公司已将ANAB公司用于治疗类风湿性关节炎的PD-1激动剂peresolimab从其产品线中撤出。
** Leerink Partners 的分析师在一份说明中写道:"临床项目的终止对 ANAB 的 PD-1 激动剂罗利单抗的前景是不利的。
** 截至上一交易日收盘,ANAB 的年累计涨幅约为 44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.